Jochen Karl Rössler

Prof. Dr. Jochen Karl Rössler

University Hospital of Bern, Bern, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Cell
Verified
Journal Article
Closed access
DSDominik Sturm
Dominik Sturm
BOBrent A. Orr
Brent A. Orr
UTUmut H. Toprak
Umut H. Toprak
VHVolker Hovestadt
Volker Hovestadt
DJDavid T.W. Jones
David T.W. Jones
MKMarcel Kool
Marcel Kool

25 July 2012 in Nature
Verified
Journal Article
Open access
PDF file
DJDavid T. W. Jones
David T. W. Jones
NJNatalie Jäger
Natalie Jäger
MKMarcel Kool
Marcel Kool
TZThomas Zichner
Thomas Zichner
BHBarbara Hutter
Barbara Hutter
PLPeter Lichter
Peter Lichter
Medulloblastoma is the most common brain tumour in children; using whole-genome sequencing of tumour samples the authors show that the clinically challenging Group 3 and 4 tumours can be tetraploid, and reveal the expression of the first medulloblastoma fusion genes identified. Medulloblastoma is the most common malignant brain tumour in children. Four papers published in the 2 August 2012 issue of Nature use whole-genome and other sequencing techniques to produce a detailed picture of the genetics and genomics of this condition. Notable findings include the identification of recurrent mutations in genes not previously implicated in medulloblastoma, with significant genetic differences associated with the four biologically distinct subgroups and clinical outcomes in each. Potential avenues for therapy are suggested by the identification of targetable somatic copy-number alterations, including recurrent events targeting TGFβ signalling in Group 3, and NF-κB signalling in Group 4 medulloblastomas. Medulloblastoma is an aggressively growing tumour, arising in the cerebellum or medulla/brain stem. It is the most common malignant brain tumour in children, and shows tremendous biological and clinical heterogeneity1. Despite recent treatment advances, approximately 40% of children experience tumour recurrence, and 30% will die from their disease. Those who survive often have a significantly reduced quality of life. Four tumour subgroups with distinct clinical, biological and genetic profiles are currently identified2,3. WNT tumours, showing activated wingless pathway signalling, carry a favourable prognosis under current treatment regimens4. SHH tumours show hedgehog pathway activation, and have an intermediate prognosis2. Group 3 and 4 tumours are molecularly less well characterized, and also present the greatest clinical challenges2,3,5. The full repertoire of genetic events driving this distinction, however, remains unclear. Here we describe an integrative deep-sequencing analysis of 125 tumour–normal pairs, conducted as part of the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. Tetraploidy was identified as a frequent early event in Group 3 and 4 tumours, and a positive correlation between patient age and mutation rate was observed. Several recurrent mutations were identified, both in known medulloblastoma-related genes (CTNNB1, PTCH1, MLL2, SMARCA4) and in genes not previously linked to this tumour (DDX3X, CTDNEP1, KDM6A, TBR1), often in subgroup-specific patterns. RNA sequencing confirmed these alterations, and revealed the expression of what are, to our knowledge, the first medulloblastoma fusion genes identified. Chromatin modifiers were frequently altered across all subgroups. These findings enhance our understanding of the genomic complexity and heterogeneity underlying medulloblastoma, and provide several potential targets for new therapeutics, especially for Group 3 and 4 patients.

7 June 2002 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JWJoerg Wilting
Joerg Wilting
MPMaria Papoutsi
Maria Papoutsi
BCBodo Christ
Bodo Christ
KNKypros Herodotos Nicolaides
Kypros Herodotos Nicolaides
CKConstantin S. von Kaisenberg
Constantin S. von Kaisenberg
Jochen Karl RösslerJochen Karl Rössler
Jochen Karl Rössler
Detection of lymphatic endothelal cells (LECs) has been problematic because of the lack of specific markers. The homeobox transcription factor Prox1 is expressed in LECs of murine and avian embryos. We have studied expression of Prox1 in human tissues with immunofluorescence. In 19‐wk‐old human fetuses, Prox1 and vascular endothelial growth factor receptor‐3 (VEGFR‐3) are coexpressed in LECs of lymphatic trunks and lymphatic capillaries. Prox1 is located in the nucleus, and its expression is mutually exclusive with that of the blood vascular marker PAL‐E. Prox1 is a constitutive marker of LECs and is found in tissues of healthy adults and lymphedema patients. Blood vascular endothelial cells (BECs) of hemangiomas express CD31 and CD34, but not Prox1. A subset of these cells is positive for VEGFR‐3. Lymphatics in the periphery of hemangiomas express Prox1 and CD31, but not CD34. In lymphangiomas, LECs express Prox1, CD31, and VEGFR‐3, but rarely CD34. In the stroma, spindle‐shaped CD34‐positive cells are present. We show that Prox1 is a reliable marker for LECs in normal and pathologic human tissues, coexpressed with VEGFR‐3 and CD31. VEGFR‐3 and CD34 are less reliable markers for LECs and BECs, respectively, because exceptions from their normal expression patterns are found in pathologic tissues.

1 December 2002 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ODOrly Dgany
Orly Dgany
NANili Avidan
Nili Avidan
JDJean Delaunay
Jean Delaunay
TKTatyana Krasnov
Tatyana Krasnov
LSLea Shalmon
Lea Shalmon
HTHannah Tamary
Hannah Tamary

1 August 2010 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JMJuliette Mazereeuw-Hautier
Juliette Mazereeuw-Hautier
PHPeter H. Hoeger
Peter H. Hoeger
SBSarah Benlahrech
Sarah Benlahrech
AAAmir Ammour
Amir Ammour
PBPierre Broue
Pierre Broue
CBChristine Bodemer
Christine Bodemer

20 November 2012 in Journal of Pediatric Psychology
Verified
Journal Article
Open access
PDF file
OMOrnella Masnari
Ornella Masnari
CSClemens Schiestl
Clemens Schiestl
Jochen Karl RösslerJochen Karl Rössler
Jochen Karl Rössler
SGStefanie K. Gütlein
Stefanie K. Gütlein
KNKathrin Neuhaus
Kathrin Neuhaus
MLMarkus A. Landolt
Markus A. Landolt
Objectives This cross-sectional study assessed psychological adjustment and health-related quality of life (HRQOL) in children and adolescents with congenital or acquired facial differences and identified potential predictors of adjustment. Methods Data were obtained from 88 children, ages 9 months to 16 years, by means of parent questionnaires (n = 86) and standardized interviews with children ≥7 years old (n = 31). Evaluation measures included the Child Behavior Checklist (CBCL), KIDSCREEN-27, TNO-AZL Preschool Quality of Life Questionnaire (TAPQOL), and Perceived Stigmatization Questionnaire. Results Psychological adjustment, as measured by the CBCL, was within norms. Parent-reported HRQOL was good in preschool children. Parent- and self-reported HRQOL of participants 7–16 years old was impaired in several dimensions, including psychological well-being. Psychological adjustment (especially internalizing behavior problems) and HRQOL were predicted primarily by perceived stigmatization. Conclusions Identification of stigma experiences and appropriate support may be crucial to enhancing psychological adjustment and quality of life in children with facial disfigurement.